Evolving Practices: Navigating Patient Care in Newly Diagnosed & R/R Multiple Myeloma

EP. 11: Adverse Event Management with Bispecifics

November 5th 2025

Panelists discuss how they manage adverse events with bispecifics through universal IVIg administration from treatment initiation, comprehensive infection prophylaxis, and growth factor support for cytopenias.

EP. 12: Dose Modifications with Bispecifics

November 5th 2025

Panelists discuss how they modify bispecific dosing intervals based on treatment response rather than dose intensity, extending administration frequency to every two or four weeks once patients achieve deeper responses.

EP. 13: Real-world Outcomes with Talquetamab

November 12th 2025

Panelists discuss how they manage talquetamab-specific toxicities including dysgeusia and nail/skin changes through patient preparation, dietary modifications with umami-rich foods, emollients, and extended dosing intervals.

EP. 14: Operationalizing Bispecifics with Other Sites

November 12th 2025

Panelists discuss how they collaborate with community oncology partners to expand bispecific antibody delivery, emphasizing that acute toxicities occur early at academic centers while maintenance dosing can be safely managed locally.